Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Jio Financial Services Ltd., Tata Chemicals Ltd., Ircon International Ltd., and Dr. Reddy's Laboratories Ltd. are among the ...

Dr. Reddys Laboratories experiences a slight decrease of -0.09% in its monthly returns, despite a notable three-month return of 10.53%.

Dr. Reddy's Laboratories Ltd. closed 8.46% below its 52-week high of 1,420.20 rupees, which the company reached on August 21st.

Dr. Reddy's Laboratories Ltd. closed 9.41% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Welcome to the Dr Reddys Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent stocks in the market. Stay on top of the game with our comprehensive ...

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

Dr Reddy’s Laboratories ( ($RDY) ) has issued an update. On July 23, 2025, Dr. Reddy’s Laboratories announced its financial results for the ...

Hyderabad: Dr. Reddy’s Laboratories Ltd has announced an investment of Rs 565.4 crore in its step-down wholly owned ...